Androgen deprivation therapy prevents bladder cancer recurrence

被引:107
作者
Izumi, Koji [1 ]
Taguri, Masataka [2 ]
Miyamoto, Hiroshi [3 ,4 ]
Hara, Yoshinori [5 ]
Kishida, Takeshi [6 ]
Chiba, Kimio [7 ]
Murai, Tetsuo [8 ]
Hirai, Kotaro [9 ]
Suzuki, Kotaro [10 ]
Fujinami, Kiyoshi [11 ]
Ueki, Teiichiro [12 ]
Udagawa, Koichi [13 ]
Kitami, Kazuo [14 ]
Moriyama, Masatoshi [15 ]
Miyoshi, Yasuhide [16 ]
Tsuchiya, Futoshi [17 ]
Ikeda, Ichiro [18 ]
Kobayashi, Kazuki [19 ]
Sato, Maho [2 ]
Morita, Satoshi [20 ]
Noguchi, Kazumi [16 ]
Uemura, Hiroji
机构
[1] Yokohama City Univ, Grasduate Sch Med, Dept Urol, Yokohama, Kanagawa 232, Japan
[2] Yokohama City Univ, Med Ctr, Dept Biostat & Epidemiol, Yokohama, Kanagawa 232, Japan
[3] Johns Hopkins Univ, Sch Med, Dept Pathol, Baltimore, MD 21205 USA
[4] Johns Hopkins Univ, Sch Med, Dept Urol, Baltimore, MD 21205 USA
[5] Odawara Municipal Hosp, Dept Urol, Odawara, Kanagawa, Japan
[6] Kanagawa Canc Ctr, Dept Urol, Yokohama, Kanagawa 2410815, Japan
[7] Kawasaki Municipal Ida Hosp, Dept Urol, Kawasaki, Kanagawa, Japan
[8] Int Goodwill Hosp, Dept Urol, Yokohama, Kanagawa, Japan
[9] Sagamihara Natl Hosp, Dept Urol, Sagamihara, Kanagawa, Japan
[10] Saiseikai Yokohamashi Nanbu Hosp, Dept Urol, Yokohama, Kanagawa, Japan
[11] Chigasaki Municipal Hosp, Dept Urol, Chigasaki, Kanagawa, Japan
[12] Japanese Red Cross Hadano Hosp, Dept Urol, Hadano, Japan
[13] Hiratsuka Kyousai Hosp, Dept Urol, Hiratsuka, Kanagawa, Japan
[14] Fujisawa City Hosp, Dept Urol, Fujisawa, Kanagawa, Japan
[15] Yokohama Municipal Citizens Hosp, Dept Urol, Yokohama, Kanagawa, Japan
[16] Yokohama City Univ, Med Ctr, Dept Urol, Yokohama, Kanagawa 232, Japan
[17] Yokohama City Minato Red Cross Hosp, Dept Urol, Yokohama, Kanagawa, Japan
[18] Yokohama Minami Kyousai Hosp, Dept Urol, Yokohama, Kanagawa, Japan
[19] Yokosuka Kyousai Hosp, Dept Urol, Yokosuka, Kanagawa, Japan
[20] Kyoto Univ, Grad Sch Med, Dept Biomed Stat & Bioinformat, Kyoto, Japan
关键词
Bladder cancer; recurrence; androgen; androgen deprivation therapy; PROSTATE-CANCER; RECEPTOR; PROGRESSION; EXPRESSION; RISK; TUMORIGENESIS; MICE; MEN;
D O I
10.18632/oncotarget.2851
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Although accumulating preclinical evidence indicates the involvement of androgen receptor signals in bladder cancer (BC) development, its clinical relevance remains unclear. We aimed to evaluate the predictive role of androgen deprivation therapy (ADT) in BC recurrence in prostate cancer (PC) patients. We retrospectively reviewed 20,328 patients with PC diagnosed during 19912013 and identified 239 (1.2%) men having primary BC. After excluding ineligible patients, 162 patients made up a final cohort. With a median follow-up of 62 months, 38 (50%) of 76 control patients without ADT experienced BC recurrence, while 19 (22%) of 86 did in ADT group. Thus, patients having received ADT for their PC showed a significantly lower risk of BC recurrence (5-year actuarial recurrence-free survival: 76% v 40%; P < 0.001) and also had a significantly smaller number of recurrence episodes (5-year cumulative recurrence: 0.44 v 1.54; P < 0.001), compared to the control patients. A multivariable analysis revealed ADT as an independent prognosticator (hazard ratio, 0.29; 95% confidence interval, 0.17-0.49) for BC recurrence. This is the first clinical study showing that ADT significantly reduces the risk of BC recurrence.
引用
收藏
页码:12665 / 12674
页数:10
相关论文
共 32 条
[1]   Characteristics of patients with prostate cancer who have initially been treated by hormone therapy in Japan: J-CaP surveillance [J].
Akaza, H ;
Usami, M ;
Hinotsu, S ;
Ogawa, O ;
Kagawa, S ;
Kitamura, T ;
Tsukamoto, T ;
Naito, S ;
Hirao, Y ;
Murai, M ;
Yamanaka, H .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2004, 34 (06) :329-336
[2]   COX REGRESSION-MODEL FOR COUNTING-PROCESSES - A LARGE SAMPLE STUDY [J].
ANDERSEN, PK ;
GILL, RD .
ANNALS OF STATISTICS, 1982, 10 (04) :1100-1120
[3]   ANALYSIS OF SURVIVAL BY TUMOR RESPONSE [J].
ANDERSON, JR ;
CAIN, KC ;
GELBER, RD .
JOURNAL OF CLINICAL ONCOLOGY, 1983, 1 (11) :710-719
[4]   Bladder cancer incidence and risk factors in men with prostate cancer: Results from cancer of the prostate strategic urologic research endeavor [J].
Boorjian, Stephen ;
Cowan, Janet E. ;
Konety, Badrinath R. ;
DuChane, Janeen ;
Tewari, Ashutosh ;
Carroll, Peter R. ;
Kane, Christopher J. .
JOURNAL OF UROLOGY, 2007, 177 (03) :883-887
[5]   Expression and significance of androgen receptor coactivators in urothelial carcinoma of the bladder [J].
Boorjian, Stephen A. ;
Heemers, Hannelore V. ;
Frank, Igor ;
Farmer, Sara A. ;
Schmidt, Lucy J. ;
Sebo, Thomas J. ;
Tindall, Donald J. .
ENDOCRINE-RELATED CANCER, 2009, 16 (01) :123-137
[6]   Association Between Smoking and Risk of Bladder Cancer Among Men and Women [J].
Freedman, Neal D. ;
Silverman, Debra T. ;
Hollenbeck, Albert R. ;
Schatzkin, Arthur ;
Abnet, Christian C. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 306 (07) :737-745
[7]   Gender-specific differences in muscle-invasive bladder cancer: the concept of sex steroid sensitivity [J].
Gakis, Georgios ;
Stenzl, Arnulf .
WORLD JOURNAL OF UROLOGY, 2013, 31 (05) :1059-1064
[8]   UNEXPLAINED EXCESS RISK OF BLADDER-CANCER IN MEN [J].
HARTGE, P ;
HARVEY, EB ;
LINEHAN, WM ;
SILVERMAN, DT ;
SULLIVAN, JW ;
HOOVER, RN ;
FRAUMENI, JF .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1990, 82 (20) :1636-1640
[9]   Epidermal growth factor enhances androgen receptor-mediated bladder cancer progression and invasion via potentiation of AR transactivation [J].
Hsieh, Teng-Fu ;
Chen, Chi-Cheng ;
Ma, Wen-Lung ;
Chuang, Wei-Min ;
Hung, Xiao-Fan ;
Tsai, Yi-Ru ;
Lin, Meng-Hsueh Amanda ;
Zhang, Qiaoxia ;
Zhang, Caixia ;
Chang, Chawnshang ;
Shyr, Chih-Rong .
ONCOLOGY REPORTS, 2013, 30 (06) :2917-2922
[10]   Estrogen Receptor Alpha Prevents Bladder Cancer Development via INPP4B inhibited Akt Pathway in vitro and in vivo [J].
Hsu, Iawen ;
Yeh, Chiuan-Ren ;
Slavin, Spencer ;
Miyamoto, Hiroshi ;
Netto, George J. ;
Tsai, Yu-Chieh ;
Muyan, Mesut ;
Wu, Xue-Ru ;
Messing, Edward M. ;
Guancial, Elizabeth A. ;
Yeh, Shuyuan .
ONCOTARGET, 2014, 5 (17) :7917-7935